Astrazeneca PLC (AZN) News
Filter AZN News Items
AZN News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest AZN News From Around the Web
Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.
AstraZeneca (AZN) says it signed new agreements aimed at broadening global distribution of a coronavirus vaccine being developed by Oxford University researchers.In one deal, AstraZeneca says it will receive $750M from the Coalition for Epidemic Preparedness Innovations to manufacture and allocate 300M doses on a "no-profit" basis for a global...
Accent Therapeutics and AstraZeneca (AZN) will collaborate to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer. Under the terms of agreement, Accent will be responsible for research, development and commercialization activities for a nominated preclinical program through to the end of Phase I clinical...
The drugs giant says it can double the production of a potential vaccine after backing by Bill Gates.
Company will increase manufacturing capability after striking additional deal worth £595m
Over 100 vaccines are currently in the race to end the Covid-19 pandemic
Drugmaker AstraZeneca has doubled manufacturing capacity for its potential coronavirus vaccine to two billion doses in a handful of deals involving Microsoft billionaire Bill Gates that guarantee early supply to lower income countries.
CityAM - Drugs giant Astrazeneca has made deals that will mean it can deliver 2bn doses of Oxford University’s potential coronavirus vaccine,
The Trump administration is prioritizing five COVID-19 vaccine programs, but ex-FDA chief Dr. Scott Gottlieb said the White House needs to spread its bets. What Happened The Trump administration is betting that five companies have the highest chance of producing a working vaccine against COVID-19. They are: AstraZeneca plc (NYSE: AZN ), Johnson & Johnson (NYSE: JNJ ), Merck & Co, Inc. (NYSE: MRK ), Moderna Inc (NASDAQ: MRNA ) and Pfizer Inc. (NYSE: PFE ). As part of the public-private partnership, the government will prioritize clinical … Full story available on Benzinga.com
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Fortress Biotech (NASDAQ: FBIO ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Pliant Therapeutics Inc (NASDAQ: PLRX ) (went public Wednesday) Protara Therapeutics Inc (NASDAQ: TARA ) Qiagen NV (NYSE: QGEN ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) United Therapeutics Corporation (NASDAQ:...
British drugmaker AstraZeneca has doubled manufacturing capacity for its potential coronavirus vaccine to 2 billion doses in a handful of deals involving Microsoft billionaire Bill Gates that guarantee early supply to lower-income countries. The deals with epidemic response group CEPI and vaccine alliance GAVI are backed by the World Health Organization and aim to quell…